INO Stock News: Inovio Pharmaceuticals Inc. regains the $21.00 mark and above
|- Inovio Pharmaceuticals Inc. (NASDAQ: INO) reverses Monday’s pullback.
- NASDAQ: INO seems to be attempting a consolidation around $21/22.00.
Shares of Inovio Pharmaceuticals (NASDAQ: INO) are posting decent gains and manage to return to the boundaries of the $22.00 mark on Tuesday, reversing at the same time Monday’s negative performance.
In fact, the upbeat note in NASDAQ: INO during the premarket activity contrasts with that of the broader US stock benchmark indices, which are expected to open on the negative side reflecting investors’ reassessment of the economic prospect vs. the advanced of the coronavirus pandemic.
Regarding the pandemic, Director of the National Institute of Allergy and Infectious Diseases A.Fauci warned in an interview that protection of a vaccine may be “finite”.
INO Stock Quote
As of writing NASDAQ: INO is up 1.55% at $21.25 and a surpass of $33.79 (monthly high Jun.23) would expose $40.00 (high September 2000) and then $54.00 (high July 2000). On the other hand, the next support is located at $16.92 (monthly high May 20) seconded by $14.89 (55-day SMA) and finally $11.13 (monthly high Jun.8).
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.